Filing Details
- Accession Number:
- 0001209191-20-002418
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2020-01-07 21:00:11
- Reporting Period:
- 2019-12-26
- Accepted Time:
- 2020-01-07 21:00:11
- Original Submission Date:
- 2019-12-30
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1478320 | Adaptive Biotechnologies Corp | ADPT | () | 4/A |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1202785 | Eric Dobmeier | C/O Adaptive Biotechnologies Corp. Suite 200 Seattle WA 98102 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-12-26 | 15,000 | $6.32 | 15,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-12-26 | 14,998 | $29.29 | 2 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-26 | 2 | $29.91 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-12-26 | 15,000 | $0.00 | 15,000 | $6.32 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 85,000 | 2026-10-18 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019.
- The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $28.85 to 29.73, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- The options vested with respect to 1/4 of the reporting person's shares on September 28, 2017, with an additional 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Billionaire Hedge Funds
